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Automated  microﬂuidic  devices  are  a promising  route  towards  a point-of-care  autologous  cell  therapy.
The  initial  steps  of induced  pluripotent  stem  cell  (iPSC)  derivation  involve  transfection  and  long  term
cell  culture.  Integration  of these  steps  would  help  reduce  the cost  and  footprint  of  micro-scale  devices
with  applications  in cell reprogramming  or  gene  correction.  Current  examples  of  transfection  integration
focus  on  maximising  efﬁciency  rather  than  viable  long-term  culture.  Here  we  look  for  whole  process
compatibility  by integrating  automated  transfection  with  a perfused  microﬂuidic  device  designed  forutomated transfection
icroﬂuidic cell culture
utologous cell therapy
ell culture
mbryonic stem cells
homogeneous  culture  conditions.  The  injection  process  was  characterised  using  ﬂuorescein  to  establish
a  LabVIEW-based  routine  for user-deﬁned  automation.  Proof-of-concept  is  demonstrated  by chemically
transfecting  a GFP  plasmid  into  mouse  embryonic  stem  cells  (mESCs).  Cells  transfected  in the  device
showed  an improvement  in  efﬁciency  (34%,  n  = 3)  compared  with  standard  protocols  (17.2%,  n  =  3).  This
represents  a ﬁrst step  towards  microﬂuidic  processing  systems  for cell reprogramming  or  gene therapy.
©  2016  The  Authors.  Published  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license. Introduction
There is a need to develop systems for the safe and economi-
al production of cell therapies [1]. Autologous cell therapies only
equire a small starting cell population from a patient blood or
kin sample. To derive iPSCs this somatic population needs to be
ransfected with pluripotent factors and maintained in stable long-
erm culture. Once derived, these cells can be further expanded and
ifferentiated in downstream processing steps for transplantation
ack into the patient. First clinical trials for such autologous ther-
pies are already underway in Japan for the treatment of macular
egeneration. For this therapy, a small sheet consisting of retinal
igment epithelial (RPE) cells (5 × 104 cells) is transplanted into
he patient’s retina [2,3]. A scale-down approach to bioprocess-
ng particularly beneﬁts treatments that require low cell input for
ransplant, such as required for an RPE-retina graft [4].
A key goal in bioprocessing is process integration to simplify
nit operations, shorten residence times and reduce footprints
5,6]. Integration can have additional advantages in cell processing,
uch as increasing cell viability by reducing the need for enzymaticPlease cite this article in press as: W.  Raimes, et al., Transfection in 
Biochem (2016), http://dx.doi.org/10.1016/j.procbio.2016.09.006
etachment [7]. A recent example of integration in cell process-
ng was demonstrated with cell expansion and differentiation in a
ingle stirred reactor, where micro-carriers have been used to con-
∗ Corresponding author.
E-mail address: n.szita@ucl.ac.uk (N. Szita).
ttp://dx.doi.org/10.1016/j.procbio.2016.09.006
359-5113/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
vert human pluripotent stem cells (hPSCs) into cardiomyocytes or
neural progenitors. This was achieved with a high cell yield, low
chance of contamination and a controlled aggregate size [6,8]. A
scale-down approach to autologous cell therapy presents an ideal
platform to test and validate integration of unit operation steps.
Transfection and long-term culture are important steps speciﬁc to
iPSC therapies that could beneﬁt from integration.
Electroporation is often regarded as having the highest efﬁ-
ciency of currently available micro-scale transfection approaches
[9]. For example, cells were recently cultured on a porous poly-
carbonate substrate and transfected by localised electroporation
to maintain high cell viability [10]. Integration of electrodes, how-
ever, typically increases the complexity of both device design and
control [11]. Chemical transfection is a simpler method, and efﬁ-
cacy and viability continue to improve with each new commercial
reagent [12]. It is important that transfecting agents are introduced
in an automated fashion to minimise environmental ﬂuctuations or
operator bias, which are more likely to occur with manual proce-
dures, and ultimately to improve robustness and reproducibility of
the transfection process. A number of microﬂuidic culture devices
have demonstrated chemical transfection of cultured cells [13–16].
Examples include a digitally controlled cell-microchip with paral-
lel circular culture chambers [13], and a self-contained system withperfused microﬂuidic cell culture devices: A case study, Process
near-chip peristaltic micro-pumps [16], both designed for combi-
natorial cell-based assays.
Integrated transfection devices described thus far compromise
on two  aspects essential for long-term stem cell culture: a uniform
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ulture microenvironment and real-time analysis of growth kinet-
cs and transfection outcome. To avoid compromise we integrate
 two-position valve to automate the injection of a transfection
eagent upstream of a microﬂuidic device that we previously devel-
ped and characterised for the long-term perfusion culture of
dherent stem cells [17]. Our device offers uniform medium ﬂow
ver the cell culture chamber and control over the dissolved gas
oncentrations [17,18], and a fully automated and on-line culture
onitoring system [19]. Furthermore, we successfully demonstrate
ransfection of mouse embryonic stem cells (mESCs), and we com-
are the efﬁciency of the transfection in the microﬂuidic device
ith a well-established manual culture protocol.
. Materials and methods
.1. Fabrication of the microﬂuidic cell culture device
The microﬂuidic culture device was fabricated according to
acown et al. [17]. Gaskets, gas-permeable lids and the microﬂu-
dic chip were cast from poly(dimethylsiloxane) (PDMS, Sylgard
84, Dow Corning, USA). A rigid polycarbonate holder in a screw-
own aluminium frame was used to compress the microﬂuidic
hip, which contained the ﬂuidic channels and the culture cham-
er, against a tissue-culture polystyrene (TC-PS) microscope slide
260225, Elektron Technology Ltd, UK). The culture surface was
.52 cm2 and the lid deﬁned the height of the perfusion chamber
t 450 m,  giving a chamber volume of ∼25 L.Please cite this article in press as: W.  Raimes, et al., Transfection in 
Biochem (2016), http://dx.doi.org/10.1016/j.procbio.2016.09.006
.2. Pressure-Driven pumping system
The pressure-driven pumping system consisted of a gas supply
21% O2, 5% CO2, N2; BOC, UK) connected to a ﬂow control sys-
ig. 1. (A) A schematic of the perfusion system with feedback from the ﬂow meter contr
ransfection mixture from the reagent reservoir is pushed into the injection loop by gas
eagent  will move into the chip. (B) The two possible positions of the injection valve: X = r
evice. PRESS
istry xxx (2016) xxx–xxx
tem (OB1, Elveﬂow, France) which fed into a medium reservoir
(DURAN® bottle with GL-45 cap, Schott AG, Germany). The pressure
was regulated by feedback control for a set ﬂow rate of 5 L min−1.
The outlet of the medium reservoir was connected to a ﬂow sensor
(MFS 2, Elveﬂow, France), which fed into a low pressure, six-port
injection valve (C22-3186EH, VICI AG International) with a 50 L
injection loop (Fig. 1A). The ﬂow control system and injection valve
were automated using LabVIEW (National Instruments, USA). The
microﬂuidic culture device connected with the injection valve via
a 10 cm long, 0.0635 mm inner diameter (ID) tubing (PEEK, IDEX
Health & Science, USA). The device parts, medium reservoir and
tubing were sterilised by autoclave and assembled in a biosafety
cabinet under sterile conditions.
2.3. Cell culture
Mouse ESC were maintained as previously reported by Macown
et al. [17]. The TC-PS slide was coated with 0.1% (w/v) gelatin
(G1890, Sigma-Aldrich, UK) solubilised in Dulbecco’s Phosphate
Buffer Solution (D1408, Sigma-Aldrich, UK) for 15 min  at room
temperature. The mESC culture medium consisted of knock-out
Dulbecco’s modiﬁed Eagle medium (10829-018, Life Technologies,
UK) supplemented with 15% v/v fetal bovine serum (26140-079,
Life Technologies, UK). Priming and seeding of the microﬂuidic cell
culture device was  performed as described by Macown et al. [17].
Brieﬂy, a suspension of mESCs (in culture medium) were seeded
by pipette at a density of 2 × 105 cells.cm−2. Cells were allowed toperfused microﬂuidic cell culture devices: A case study, Process
attach for 6 h in a 37 ◦C incubator before the start of perfusion. Dur-
ing perfusion the device was placed on the stage of an automated
microscope (Eclipse Ti-E, Nikon Instruments, UK) at 37 ◦C in a cage
incubator (Okolab, Italy).
olling the ﬂow of culture medium into the microﬂuidic cell culture device (MFCD).
 from the pressure regulator; once it has ﬁlled the loop, the valve will switch and
eagent loading into loop, and Y = reagent injection into the microﬂuidic cell culture
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.4. Automated transfection in microﬂuidic culture device
Cells were transfected 24 h after the start of perfusion. The trans-
ection mix  consisted of a 2:3 ratio mixture of Lipofectamine®
000 (L3000-015, Life Technologies, UK) and GFP episomal plas-
id  (pCXLE-GFP, 27082, Addgene) in serum-free culture medium,
ollowing the protocol provided by Life Technologies (UK). 100 L
f the transfection mix, containing 1 g plasmid DNA and 1.5 L
ipofectamine, was placed in a 1.5 mL  Eppendorf® microﬂuidic
eservoir (KRXS, Elveﬂow, France). The reservoir was  connected to
he injection valve sample loop and to the pressure-driven pumping
ystem (Fig. 1A). A LabVIEW routine (National Instruments, USA)
utomated the loading of the 50 L injection loop from a second
ressure channel, followed by a valve switch to ﬂow the transfec-
ion mix  to the culture chamber which held a maximum volume of
25 L (Fig. 1B). Once the culture chamber was  full of the trans-
ection mixture, the pressure of the pumping system was  switched
ff for 2 h. After this time culture medium perfusion was resumed
t a ﬂow rate of 5 L min−1 to ﬂush the transfection mix  out of
he culture chamber. Phase contrast microscopy images were taken
4 h post-transfection at 10×magniﬁcation using the microscope’s
igital camera (DS-Fi1, Nikon Instruments, UK).
.5. Transfection in well plates
Mouse ESCs were seeded in TC-PS 24-well plates (#3524, Corn-
ng, USA) at a density of 2 × 105 cells.cm−2. The transfection mix
escribed in section 2.4 (100 L per well) was incubated for 10 min
t room temperature and added to the culture wells containing
00 L serum-free culture medium. Cells were then incubated for
 2 h period at 37 ◦C. After transfection, cells were incubated for a
4 h period in fresh medium containing serum. Pictures were taken
sing a digital ﬂuorescence microscope (EVOS® FL AMEFC4300, Life
echnologies, UK).
.6. Transfection analysis
Cells (both from device and well plates) were enzymatically
etached (TrypLE select, 12563029, Life Technologies, UK) 24 h post
ransfection, and re-suspended in fresh medium before being ana-
ysed with a ﬂow cytometer (BD-Accuri C6, BD Biosciences, UK). GFP
xpression was assessed with the FL1 detector of the ﬂow cytome-
er. Transfected samples results were gated, excluding 99% of the
n-transfected negative control population, to calculate the per-
entage of GFP-positive cells. All experiments were conducted in
riplicates.
.7. Injection time characterisation
A 20 g mL−1 ﬂuorescein solution (F6377-100G, Sigma-Aldrich)
as used to measure injection times and concentrations in the cul-
ure chamber of the microﬂuidic device. Progression of the solution
n the chamber was assessed by ﬂuorescence microscopy imaging
t 2× magniﬁcation. Images were acquired every minute during
njection and wash-out of the solution, and every 30 min  during
he static period. Pixel intensities at different injection times were
easured across the centre of the chamber using ImageJ [20]. A cal-
bration curve was established measuring different concentrations
f ﬂuorescein in static conditions (no ﬂow). To reduce the effect
f photo-bleaching, the microscope epiﬂuorescence lamp was  only
witched on during image acquisition.Please cite this article in press as: W.  Raimes, et al., Transfection in 
Biochem (2016), http://dx.doi.org/10.1016/j.procbio.2016.09.006
.8. Residence time distribution
A UV absorbance detector (D100 ActiPix, Paraytec Ltd, UK) for
he detection of a tracer compound was connected to the efﬂuent PRESS
istry xxx (2016) xxx–xxx 3
stream of the microﬂuidic cell culture device (Supporting Material
A). Fluid ﬂow was  delivered by a low pressure neMESYS syringe
pump (Cetoni GmbH, Germany). A 254 nm ﬁlter with a 12 nm
bandwidth (254BP12, Omega Optical Inc., USA) was  used to deter-
mine the step change between water and the tracer compound,
a 200 mgL−1 aqueous solution of l-tryptophan (Sigma, UK). The
tracer solution contained additionally 4 mM Allura red (Sigma, UK).
A calibration curve was  carried out by scanning different concen-
trations of the tracer. The cumulative response to the step change,
F(t), was deﬁned as:
F (t) = Cout (t)
Cout,max
(1)
where Cout(t) and Cout,max were the concentration of the tracer in
the outlet at time, t, and the maximum tracer concentration, respec-
tively. The step change function was plotted against the normalised
residence time, deﬁned as:
 = Q
VS
.t (2)
where Q and Vs were the ﬂow rate and the setup volume, respec-
tively. The setup volume comprised the volume of the microﬂuidic
culture device, the downstream ﬂuidic connectors and the mea-
surement capillary (100 m inner diameter, Postnova Analytics UK
Ltd, UK).
The percentage of stagnancy (PS) was calculated as
PS (%) =  − e

× 100 (3)
where  and e were the residence time (Vs/F) and the apparent
mean residence time, calculated from the F(t), respectively. Mea-
surements were performed in triplicates.
3. Results
3.1. Characterisation of residence times
In order to achieve proper characterisation of the transfection
efﬁciency and to enable meaningful comparison with the batch
operation modes of well plates, we conducted an analysis of the
residence time distribution (RTD) in our setup (Fig. 2A). The RTD
analysis of the culture device showed that the percentage of stag-
nancy was less than 1% (when compared with Cout,max, as described
in Eq. (1)). This indicates that in the culture chamber all cells
are exposed to an equal concentration of transfection reagent. A
ﬂuorescein solution injection showed that 89.5% of the theoreti-
cal maximum concentration was reached ∼13 min  post injection
(Fig. 2B). Multiplying this time (∼13 min) with the set ﬂow rate
(5 L min−1) gave us an accurate estimation of the pre-chamber
volume (65 L) for the LabVIEW-based automation of the setup.
During the 2 h-long static phase, the relative ﬂuorescein concentra-
tion decreased from 89.5% to 84.8% before the chamber was ﬂushed
(Fig. 2B).
3.2. Microﬂuidic cell culture device transfection
Twenty-four hours after transfection, GFP expression was visu-
ally assessed with ﬂuorescence microscopy in the device (Fig. 3A)
and the control wells (Fig. 3B). Additionally, ﬂow cytometry was
used to determine the percentage of GFP-positive cells in both cell
populations (Supporting Material B). In the 24 well plate controls
17.2 ± 0.8% of the cells were GFP-positive. In the valve-mediatedperfused microﬂuidic cell culture devices: A case study, Process
transfection 34.0 ± 3.9% of the cells in the device expressed GFP
(Fig. 3C). A comparison of the average median ﬂuorescence inten-
sity (MFI) values of the GFP expressing populations indicates that
cells transfected in the device had an MFI  three times higher
Please cite this article in press as: W.  Raimes, et al., Transfection in perfused microﬂuidic cell culture devices: A case study, Process
Biochem (2016), http://dx.doi.org/10.1016/j.procbio.2016.09.006
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Fig. 2. (A) Cumulative response, F(), of the normalised residence time, , of the microﬂuidic cell culture device (MFCD). The tracer concentration was 0.2 gL−1 delivered at
a  ﬂow rate of 5 L min−1. LFR − laminar ﬂow reactor. (B) Residence time of ﬂuorescein injected into a microﬂuidic cell culture device via an automated two-way valve at
5  L min−1. After 13 min, maximal concentration (89.5%) was  reached and ﬂow was  switched off. After 120 min  ﬂow resumed ﬂushing the device. Images were taken every
minute  for injection/ﬂushing and every 30 min  during the static period. Values are the mean of three independent experiments, error bars display standard deviation.
Fig. 3. (A, B) 10 × FITC and phase contrast merged images of transfected cells in the microﬂuidic cell culture device (MFCD) and 24-well plate, respectively. Scale bar: 200 m.
(C)  GFP expression and median ﬂuorescence intensity for mESCs transfected with lipofectamine in the automated MFCD and a 24 well plate, measured using ﬂow cytometry.
Values  are the mean of three independent experiments, error bars display standard deviation.
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8.81 × 105 ± 2.89 × 105 RFU) than those transfected in the well
3.13 × 105 ± 0.7 × 104 RFU) (Fig. 3C).
. Discussion
A uniform concentration of transfection mix  across the culture
urface is necessary for efﬁcient chemical transfection. In addi-
ion, a precise knowledge on the residence time of the transfection
gent in the microﬂuidic culture chamber, i.e when the transfection
gents enter and leave the culture chamber, is required to deﬁne
he duration of reagent exposure. At the microscale, the ﬂow in the
ulture device and tubing is laminar, therefore the delivery method
ust be precisely controlled. The parabolic ﬂow proﬁle of laminar
ow systems ‘smears’ the distribution of reagent concentrations
n ﬂow. Calculating the time required for the transfection reagent
o move from the injection valve to the culture chamber by divid-
ng the ‘post-valve’ volume of the tubing by the ﬂow rate during
erfusion (5 L min−1) alone would therefore not provide an accu-
ate knowledge of when the reagent would reach the chamber.
urthermore, calculated dead-volumes are only approximations;
xperimental determination was required to gain exact knowl-
dge. As such the pre-chamber volume, i.e. the volume between
he valve and the culture chamber, was determined by multiplying
he post valve perfusion time with the set ﬂow rate. This volume
as applied in a LabVIEW event loop with real-time feedback from
he ﬂow meter each second (Supporting Material C). Once this vol-
me  reaches zero (as determined by the ﬂuorescence signal) the
aximum chamber reagent concentration has been reached and
he system automatically stops perfusion. Following this, a count-
own starts before perfusion is restarted. It is important to incubate
ransfection reagent with DNA prior to transfection to ensure for-
ation of lipo-complexes, however leaving this >15 min  can cause
 loss in transfection efﬁciency. Using the automated valve system,
e can ensure that the time taken for the reagent mix  to reach
he chamber (i.e. incubation time) remains below this protocol-
peciﬁed maximum.
It was not possible to completely saturate the culture chamber
ith ﬂuorescein solution (89.5%) due to diffusion into the carrier
edium during the injection process. The Stokes-Einstein equation
tates that the diffusion coefﬁcient is proportional to the squared
elocity of the diffusing particles, which is inversely related to the
ize of the particle. A lipo-complex (DNA:Lipid, ∼300 nm)  is larger
han a ﬂuorescein molecule (∼0.45 nm)  therefore has a lower dif-
usion rate. Thus the ﬂuorescein concentration in the chamber will
e lower than that expected for the larger lipocomplex. The fur-
her reduction in concentration seen over the full time course of
he static transfection period is due to a small amount of ﬂuores-
ein diffusion out of the culture chamber. To reduce diffusion into
he carrying medium during the injection process, the injection
oop (50 L) provided double the volume of reagent required to ﬁll
he chamber. This means that once the maximum concentration is
eached and the incubation phase begins, this excess transfection
eagent remains in the pre-chamber tubing. This will pass over the
ells at the end of the static period and therefore may  contribute to
ncreased efﬁciency present in the culture chamber, though expo-
ure time is minimal.
The 1.8-fold transfection efﬁciency increase found in the device
ompared to the well plate can be explained by both the difference
n surface-area-to-volume ratio (SA:V) and the necessary dilution
f transfection mix  in the well plate. The microﬂuidic cell cul-
ure device present a SA:V ﬁve times greater than a traditionalPlease cite this article in press as: W.  Raimes, et al., Transfection in 
Biochem (2016), http://dx.doi.org/10.1016/j.procbio.2016.09.006
ulture well in a 24 well plate with a working volume of 500 L.
his shortens dramatically the diffusion timescale of the DNA:lipid
omplexes to reach the cells. Shallow enclosed microﬂuidic chan-
els provide a clear advantage over larger open culture wells, PRESS
istry xxx (2016) xxx–xxx 5
with working volumes kept to a minimal since evaporation is no
longer a concern. An improved efﬁciency is obtained for a reduced
transfection reagent input. This proof-of-concept thus successfully
demonstrates the injection valve as a functional approach for auto-
mated in-situ transfection in the perfused microﬂuidic device.
We can estimate the diffusion coefﬁcient of lipoplexes in
medium (D) to be 10−12 m2 s−1 using the Stokes Einstein equation:
D = kBT
6pa
Where T is the absolute temperature (310.15 K), kB is the Boltz-
mann constant, p the medium viscosity (assuming that of water,
691.6 10−6 Pa.s, at 37 ◦C) and a the particle radius (assuming spher-
ical, 300 nm). We  use D to compare the characteristic time (t) of
diffusion in a two-dimensional plane between the medium height
(H) in the chamber (∼450 m)  relative to the well plate (∼10 mm)
using Einstein’s relation:
t = H
2
2D
This comparison shows that it takes over 400 times longer for
lipoplexes to diffuse across the well relative to the culture cham-
ber considering the difference in medium height alone. This can
also explain the MFI  difference between the two culture vessels;
cells in the microﬂuidic culture device received a higher individ-
ual eGFP load and therefore expressed more GFP than cells in the
well. Further investigation of diffusional properties may  be neces-
sary depending on the non-integrating reprogramming vector used
(i.e. episomal, mRNA or viral) [21].
Luni et al. recently published the ﬁrst example of iPSC con-
version in a microﬂuidic device [22]. Micro-volume conﬁnement
resulted in increased efﬁciency of iPSC conversion over traditional
well-plate methods due to an increased concentration of endoge-
nous signalling molecules. The authors used an on/off pneumatic
valve system for daily medium replenishment and transfection of
reprogramming factors. In contrast, we  present a more complex
culture system, which caters for switching between static trans-
fection and controlled medium perfusion. As a proof-of-concept
we focus here on demonstrating the beneﬁts to transfection efﬁ-
ciency at the micro-scale. As of yet, there has been no report of
perfusion used for cell reprogramming. There are however a num-
ber of advantages to the use of microﬂuidic perfusion culture. For
example, the expansion rate of iPSCs increased with continuous
perfusion relative to periodic medium changes [23]. By disrupting
endogenous signalling, perfusion can also allow for a clearer iden-
tiﬁcation of reprogramming-enhancing extrinsic factors [24,25].
5. Conclusions
We investigated transfection in a microﬂuidic device designed
for long-term adherent cell culture as a ﬁrst step towards realising
a scale-down tool that mimics the process integration necessary to
derive iPSCs from patient cell samples. A bespoke LabVIEW routine
automates the delivery of small volumes of transfection reagents to
a perfusion microﬂuidic device via a six-port injection valve. This
system is capable to be customized to account for different ﬂow
rates or incubation times in order to personalise the transfection
process. Applicability has been shown by chemically transfecting
mouse embryonic stem cells with a GFP plasmid. A higher efﬁcacy
was obtained in our device (34%) compared to standard cultureperfused microﬂuidic cell culture devices: A case study, Process
protocol (17.2%). The better performance of an automated setup,
together with the advantages of microﬂuidic devices, will ulti-
mately allow for these systems to be used for cell reprogramming
or for gene correction therapies.
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